| Segment | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Belbuca | $53.2M | $55.21M | $51.66M | $52.6M | $58.26M | $59.14M | $52.65M | $57.67M |
| Jornay PM | $7.96M | $29.28M | $28.54M | $32.63M | $41.8M | $45.89M | $38.89M | $46.06M |
| Xtampza ER | — | — | — | — | — | — | $50.77M | $45.01M |
| Nucynta ER | $19.77M | $17.54M | $19.69M | $19.95M | $22.81M | $18.54M | $18.23M | $15.72M |
| Nucynta IR | $25.36M | $24.22M | $27.42M | $26.5M | $31.99M | $29.41M | $26.08M | $14.36M |
| Azstarys | — | — | — | — | — | — | — | $12.91M |
| Symproic | $3.52M | $4.25M | $2.82M | $3.72M | $4.03M | — | $4.19M | $3.02M |
| Nucynta ER AG | — | — | — | — | — | — | $1.45M | $2.78M |
| Nucynta IR AG | — | — | — | — | — | — | $1.26M | $2.36M |
| Total | $159.3M | $181.95M | $177.76M | $188M | $209.36M | $205.45M | $193.52M | $199.88M |
Symproic and other is derived from annual filings.